Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®

This study will use retrospective data to evaluate the safety and efficacy of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) in the treatment of macular oedema due to retinal vein occlusion (RVO) in clinical practice. No intervention will be administered as part of this study.

Inclusion Criteria:

• Macular oedema in at least one eye due to branch retinal vein occlusion (BRVO) or central vein occlusion (CRVO)
• Received at least one injection of OZURDEX® in the study eye

Exclusion Criteria:

• None